Eli Historical Income Statement

LLY Stock

USD 778.62 0.38 0.05%

Historical analysis of Eli Lilly income statement accounts such as Gross Profit of 28.4 B can show how well Eli Lilly and performed in making a profits. Evaluating Eli Lilly income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Eli Lilly's future profits or losses.

Cash Flow Balance Sheet Income Statement

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Eli Lilly latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Eli Lilly is a good buy for the upcoming year.

Net Income Gross Profit

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

About Eli Income Statement Analysis

Eli Lilly Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Eli Lilly shareholders. The income statement also shows Eli investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Eli Lilly Income Statement Chart

At this time, Eli Lilly's Interest Expense is fairly stable compared to the past year. Total Revenue is likely to rise to about 35.8 B in 2024, whereas Depreciation And Amortization is likely to drop slightly above 941.5 M in 2024.

Total Revenue Gross Profit Other Operating Expenses

Total Revenue

Total revenue comprises all receipts Eli Lilly generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Eli Lilly and minus its cost of goods sold. It is profit before Eli Lilly operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Eli Lilly. It is also known as Eli Lilly overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Eli Lilly's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Eli Lilly current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

	2021	2022	2023	2024 (projected)
Gross Profit	21.0B	21.9B	27.0B	28.4B
Total Revenue	28.3B	28.5B	34.1B	35.8B

Gross Profit Total Revenue

Eli Lilly income statement Correlations

	Depreciation And Amortization	Interest Expense	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Selling General Administrative	Research Development	Net Income From Continuing Ops	Non Recurring	Non Operating Income Net Other	Selling And Marketing Expenses	Minority Interest	Tax Provision	Interest Income	Net Interest Income	Discontinued Operations	Reconciled Depreciation
Depreciation And Amortization		0.37	0.55	0.52	0.89	0.24	0.58	0.68	0.83	0.89	0.53	-0.08	0.44	0.32	0.86	0.44	-0.22	0.32	0.1	-0.09	0.21	0.18	0.16	-0.12	0.1	-0.2
Interest Expense	0.37		0.86	0.87	0.49	0.87	0.65	0.64	0.48	0.48	0.55	-0.59	0.51	0.13	0.3	0.9	0.41	-0.1	-0.53	-0.81	0.29	0.37	0.59	-0.88	0.89	-0.33
Total Revenue	0.55	0.86		1.0	0.71	0.87	0.61	0.63	0.67	0.71	0.62	-0.59	0.54	0.29	0.64	0.98	0.2	-0.12	-0.34	-0.72	0.16	0.31	0.5	-0.62	0.66	0.0
Gross Profit	0.52	0.87	1.0		0.69	0.9	0.6	0.63	0.63	0.69	0.63	-0.59	0.55	0.28	0.63	0.98	0.23	-0.14	-0.31	-0.7	0.17	0.29	0.47	-0.63	0.67	-0.02
Other Operating Expenses	0.89	0.49	0.71	0.69		0.44	0.64	0.71	0.96	0.99	0.72	-0.22	0.61	0.37	0.85	0.63	0.03	0.02	-0.09	-0.37	0.05	0.23	0.34	-0.29	0.31	-0.15
Operating Income	0.24	0.87	0.87	0.9	0.44		0.57	0.55	0.38	0.46	0.62	-0.6	0.6	0.05	0.33	0.9	0.49	-0.28	-0.41	-0.78	0.33	0.11	0.49	-0.73	0.76	-0.01
Ebit	0.58	0.65	0.61	0.6	0.64	0.57		0.99	0.65	0.61	0.63	-0.45	0.55	0.27	0.41	0.54	0.27	0.29	-0.38	-0.58	0.57	0.4	0.69	-0.53	0.51	-0.25
Ebitda	0.68	0.64	0.63	0.63	0.71	0.55	0.99		0.72	0.69	0.65	-0.42	0.57	0.3	0.51	0.56	0.21	0.31	-0.33	-0.53	0.55	0.39	0.65	-0.49	0.48	-0.25
Cost Of Revenue	0.83	0.48	0.67	0.63	0.96	0.38	0.65	0.72		0.91	0.64	-0.25	0.54	0.34	0.73	0.6	0.04	0.06	-0.28	-0.46	0.05	0.32	0.5	-0.33	0.36	-0.11
Total Operating Expenses	0.89	0.48	0.71	0.69	0.99	0.46	0.61	0.69	0.91		0.74	-0.19	0.63	0.37	0.89	0.62	0.02	0.01	-0.01	-0.32	0.05	0.19	0.26	-0.27	0.28	-0.16
Income Before Tax	0.53	0.55	0.62	0.63	0.72	0.62	0.63	0.65	0.64	0.74		0.05	0.96	0.1	0.57	0.57	0.58	-0.4	-0.15	-0.54	0.03	-0.09	0.51	-0.6	0.58	-0.43
Total Other Income Expense Net	-0.08	-0.59	-0.59	-0.59	-0.22	-0.6	-0.45	-0.42	-0.25	-0.19	0.05		0.14	-0.31	-0.08	-0.64	0.08	-0.3	0.46	0.52	-0.39	-0.6	-0.29	0.29	-0.37	-0.35
Net Income	0.44	0.51	0.54	0.55	0.61	0.6	0.55	0.57	0.54	0.63	0.96	0.14		-0.18	0.45	0.5	0.71	-0.51	-0.19	-0.55	0.09	-0.3	0.49	-0.63	0.6	-0.43
Income Tax Expense	0.32	0.13	0.29	0.28	0.37	0.05	0.27	0.3	0.34	0.37	0.1	-0.31	-0.18		0.41	0.23	-0.47	0.43	0.15	0.05	-0.17	0.79	0.05	0.14	-0.09	0.04
Selling General Administrative	0.86	0.3	0.64	0.63	0.85	0.33	0.41	0.51	0.73	0.89	0.57	-0.08	0.45	0.41		0.51	-0.22	0.06	0.32	-0.05	-0.04	0.08	0.02	-0.01	0.02	-0.02
Research Development	0.44	0.9	0.98	0.98	0.63	0.9	0.54	0.56	0.6	0.62	0.57	-0.64	0.5	0.23	0.51		0.26	-0.18	-0.46	-0.79	0.16	0.32	0.52	-0.69	0.74	-0.01
Net Income From Continuing Ops	-0.22	0.41	0.2	0.23	0.03	0.49	0.27	0.21	0.04	0.02	0.58	0.08	0.71	-0.47	-0.22	0.26		-0.7	-0.4	-0.62	0.07	-0.36	0.52	-0.71	0.69	-0.38
Non Recurring	0.32	-0.1	-0.12	-0.14	0.02	-0.28	0.29	0.31	0.06	0.01	-0.4	-0.3	-0.51	0.43	0.06	-0.18	-0.7		0.1	0.33	0.51	0.53	-0.09	0.37	-0.38	0.15
Non Operating Income Net Other	0.1	-0.53	-0.34	-0.31	-0.09	-0.41	-0.38	-0.33	-0.28	-0.01	-0.15	0.46	-0.19	0.15	0.32	-0.46	-0.4	0.1		0.82	-0.25	-0.35	-0.78	0.65	-0.67	0.07
Selling And Marketing Expenses	-0.09	-0.81	-0.72	-0.7	-0.37	-0.78	-0.58	-0.53	-0.46	-0.32	-0.54	0.52	-0.55	0.05	-0.05	-0.79	-0.62	0.33	0.82		-0.2	-0.27	-0.85	0.87	-0.9	0.15
Minority Interest	0.21	0.29	0.16	0.17	0.05	0.33	0.57	0.55	0.05	0.05	0.03	-0.39	0.09	-0.17	-0.04	0.16	0.07	0.51	-0.25	-0.2		0.04	0.29	-0.14	0.1	0.14
Tax Provision	0.18	0.37	0.31	0.29	0.23	0.11	0.4	0.39	0.32	0.19	-0.09	-0.6	-0.3	0.79	0.08	0.32	-0.36	0.53	-0.35	-0.27	0.04		0.33	-0.16	0.2	-0.05
Interest Income	0.16	0.59	0.5	0.47	0.34	0.49	0.69	0.65	0.5	0.26	0.51	-0.29	0.49	0.05	0.02	0.52	0.52	-0.09	-0.78	-0.85	0.29	0.33		-0.71	0.7	-0.19
Net Interest Income	-0.12	-0.88	-0.62	-0.63	-0.29	-0.73	-0.53	-0.49	-0.33	-0.27	-0.6	0.29	-0.63	0.14	-0.01	-0.69	-0.71	0.37	0.65	0.87	-0.14	-0.16	-0.71		-0.99	0.53
Discontinued Operations	0.1	0.89	0.66	0.67	0.31	0.76	0.51	0.48	0.36	0.28	0.58	-0.37	0.6	-0.09	0.02	0.74	0.69	-0.38	-0.67	-0.9	0.1	0.2	0.7	-0.99		-0.46
Reconciled Depreciation	-0.2	-0.33	0.0	-0.02	-0.15	-0.01	-0.25	-0.25	-0.11	-0.16	-0.43	-0.35	-0.43	0.04	-0.02	-0.01	-0.38	0.15	0.07	0.15	0.14	-0.05	-0.19	0.53	-0.46

Click cells to compare fundamentals

Eli Lilly Account Relationship Matchups

Eli Lilly income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	1.6B	1.3B	1.5B	1.5B	1.5B	941.5M
Interest Expense	400.6M	359.6M	339.8M	331.6M	485.9M	510.2M
Total Revenue	22.3B	24.5B	28.3B	28.5B	34.1B	35.8B
Gross Profit	17.6B	19.1B	21.0B	21.9B	27.0B	28.4B
Other Operating Expenses	16.5B	17.7B	20.8B	20.3B	23.8B	12.0B
Operating Income	5.0B	6.1B	6.4B	7.1B	10.3B	10.8B
Ebit	5.0B	7.6B	6.5B	7.1B	7.0B	4.3B
Ebitda	6.6B	8.9B	8.0B	8.7B	8.6B	5.2B
Cost Of Revenue	4.7B	5.5B	7.3B	6.6B	7.1B	3.6B
Total Operating Expenses	11.8B	12.2B	13.5B	13.6B	16.7B	8.4B
Income Before Tax	5.3B	7.2B	6.2B	6.8B	6.6B	3.5B
Total Other Income Expense Net	291.6M	19.1M	(201.6M)	(1.8B)	(3.8B)	(3.6B)
Net Income	4.6B	6.2B	5.6B	6.2B	5.2B	2.7B
Income Tax Expense	628M	1.0B	573.8M	561.6M	1.3B	810.6M
Selling General Administrative	6.2B	6.1B	6.4B	6.4B	6.9B	5.7B
Research Development	5.6B	6.1B	7.0B	7.2B	9.3B	9.8B
Net Income Applicable To Common Shares	8.3B	6.2B	5.6B	6.2B	7.2B	4.0B
Net Income From Continuing Ops	4.6B	6.2B	5.6B	6.2B	5.2B	4.4B
Non Recurring	2.8B	2.5B	815.2M	244.6M	281.3M	267.2M
Non Operating Income Net Other	52.4M	74.8M	291.6M	(320.9M)	(288.8M)	(274.4M)
Selling And Marketing Expenses	6.2B	1.1B	1.2B	1B	461.9M	438.8M
Minority Interest	75.7M	1.1B	92.2M	183.6M	211.1M	241.8M
Tax Provision	628M	1.0B	573.8M	561.6M	1.3B	989.6M
Interest Income	80.4M	326.6M	314.4M	268.8M	173.6M	204.8M
Net Interest Income	(320.2M)	(326.6M)	(314.4M)	(268.8M)	(312.3M)	(327.9M)
Reconciled Depreciation	1.2B	1.3B	1.5B	1.5B	1.5B	1.6B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Eli Stock Analysis

When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Eli Historical Income Statement

About Eli Income Statement Analysis

Eli Lilly Income Statement Chart

Total Revenue

Gross Profit

Other Operating Expenses

Eli Lilly income statement Correlations

Eli Lilly Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Eli Lilly income statement Accounts

Also Currently Popular

Additional Tools for Eli Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Total Operating Expenses	+ 0.99	Other Operating Expenses
Ebitda	+ 0.99	Ebit
Research Development	+ 0.98	Total Revenue
Research Development	+ 0.98	Gross Profit
Cost Of Revenue	+ 0.96	Other Operating Expenses

Discontinued Operations	- 0.99	Net Interest Income
Discontinued Operations	- 0.9	Selling And Marketing Expenses
Net Interest Income	- 0.88	Interest Expense
Interest Income	- 0.85	Selling And Marketing Expenses
Selling And Marketing Expenses	- 0.81	Interest Expense
Selling And Marketing Expenses	- 0.79	Research Development